Needham analyst Gil Blum maintained a Buy rating on Solid Biosciences today and set a price target of $16.00.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Gil Blum has given his Buy rating due to a combination of factors tied to Solid Biosciences’ advancing clinical pipeline and upcoming regulatory catalysts. He highlights that the company’s lead Duchenne muscular dystrophy (DMD) program, SGT-003, has now treated 33 patients in the INSPIRE trial without AAV-related safety issues and that enrollment is essentially complete with a target of 50–60 patients. In addition, the initiation of the randomized Phase III IMPACT study, which is expected to finish enrollment in roughly 18 months, provides a clear pathway toward potential registration. Blum also notes that the company plans to deliver a clinical update from INSPIRE, reinforcing visibility into efficacy and durability data that could support future filings.
Blum further underpins his Buy thesis by pointing to three planned FDA meetings in the first half of 2026, after which Solid intends to share the outcomes mid-year, and he sees a strong probability that the agency will endorse an accelerated approval strategy for SGT-003. He also views Solid’s broader pipeline as value-enhancing, including the first patient dosing in the Phase Ib FALCON study for Friedrich’s Ataxia (SGT-212), with initial data expected in the second half of 2026. Taken together, these clinical milestones and regulatory events concentrate substantial value inflection points in 2026, leading Blum to characterize the year as potentially transformative for the company and to reaffirm his Buy rating and $16 price target.
According to TipRanks, Blum is a 4-star analyst with an average return of 7.7% and a 39.47% success rate. Blum covers the Healthcare sector, focusing on stocks such as Autolus Therapeutics, Cartesian Therapeutics, and Mereo Biopharma Group Plc.
In another report released today, Piper Sandler also maintained a Buy rating on the stock with a $17.00 price target.